EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring

Seyyed Mohammad Yaghoubi iD, Erfan Zare iD, Sina Jafari Dargahlou, Maryam Jafari, Mahdiye Azimi, Maedeh Khoshnazar iD, Solmaz Shirjang, Behzad Mansoori iD

Cells · 04.01.2026 · 15 (1) · 83

DOI: 10.3390/cells15010083 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 04.01.2026. Verfasst von Seyyed Mohammad Yaghoubi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plant, Cell and Molecular Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz 5166616471, Iran. Hauptthemen laut MEDLINE: Prostatic Neoplasms, MicroRNAs, Early Detection of Cancer. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) is a common malignancy in men worldwide, with incidence projected to rise in the coming years. Traditional screening and diagnostic methods, such as prostate-specific antigen (PSA) testing and biopsy, face limitations in specificity and invasiveness. Circulating microRNAs (miRNAs) have emerged as stable, non-invasive biomarkers obtainable via liquid biopsies (blood, urine, semen) that could transform PCa management. These small regulatory RNAs reflect underlying tumor biology and are detectable at early disease stages, enabling improved early detection when used alongside or in place of PSA. Distinct miRNA expression patterns correlate with tumor aggressiveness. For example, miR-141 and miR-375 are elevated in metastatic cases, whereas let-7 family members and miR-326 are upregulated in aggressive disease, highlighting their prognostic value. Moreover, dynamic changes in reported miRNAs during therapy provide real-time insights into treatment response. In androgen-deprivation therapy (ADT), oncogenic miRNAs, such as miR-21 and miR-125b, increase upon resistance, whereas a decline in tumor-suppressive miRNAs, such as miR-23b/-27b, flags the transition to castration-resistant PCa (CRPC). Similarly, baseline levels of miRNAs (e.g., miR-200b/c, miR-20a) can predict chemotherapy outcomes. Integrating multi-miRNA panels has demonstrated superior accuracy for risk stratification and monitoring, paving the way for personalized treatment. Although promising, clinical implementation of miRNA-based assays requires further validation, standardization of protocols, and large-scale prospective studies. Harnessing circulating miRNAs could usher in a new era of precision oncology for PCa, improving early diagnosis, prognostication, and real-time therapeutic guidance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMicroRNAsEarly Detection of CancerHumansMaleLiquid BiopsyPrognosisBiomarkers, TumorCirculating MicroRNA

Stichwörter der Autor:innen

biomarkersearly detectionliquid biopsiesmicroRNAprognosisprostate cancertreatment monitoring

Substanzen

MicroRNAsBiomarkers, TumorCirculating MicroRNA

Autor:innen und Institutionen

  • Department of Plant, Cell and Molecular Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz 5166616471, Iran.
  • Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, Iran.
  • Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil 5371713111, Iran.
  • Students Research Committee, School of Medicine, Ardabil University of Medical Sciences, Ardabil 5618985991, Iran.
  • Department of Biophysics, Faculty of Advanced Technologies, University of Mohaghegh Ardabili, Namin 5619911367, Iran.
  • Student Research Committee, School of Medicine, Anzali International Campus, Guilan University of Medical Sciences, Rasht 4144666949, Iran.

ORCID-Profile: Seyyed Mohammad Yaghoubi, Erfan Zare, Maedeh Khoshnazar, Behzad Mansoori

Zitieren

APA

Yaghoubi, S. M., Zare, E., Jafari Dargahlou, S., Jafari, M., Azimi, M., Khoshnazar, M., Shirjang, S., & Mansoori, B. (2026). MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring. Cells, 15(1), 83. https://doi.org/10.3390/cells15010083

Vancouver

Yaghoubi SM, Zare E, Jafari Dargahlou S, Jafari M, Azimi M, Khoshnazar M, et al. MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring. Cells. 2026;15(1):83. doi:10.3390/cells15010083

BibTeX
@article{Yaghoubi2026,
  author = {Yaghoubi, Seyyed Mohammad and Zare, Erfan and Jafari Dargahlou, Sina and Jafari, Maryam and Azimi, Mahdiye and Khoshnazar, Maedeh and Shirjang, Solmaz and Mansoori, Behzad},
  title = {MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {1},
  pages = {83},
  doi = {10.3390/cells15010083}
}
Kostenlos starten →